The present investigation explored and compared the subjective responses of patients in the stable-phase of schizophrenia being treated with either olanzapine or risperidone. Several well-established, self-report inventories were used in this investigation, providing a means of assessing the impact of these medications from the perspective of the patient. The mean dosage of olanzapine (15.0mg) and risperidone (4.2mg) used in the present investigation were in line with treatment guidelines and standards of care. Findings include a highly knowledgeable sample of patients, who are satisfied with the information provided regarding their medication and treatment. Patients in both treatment groups were found to possess positive attitudes towards their medication, and a relatively high overall level of well-being and health-related quality of life. The majority of patients, in both treatment groups, expressed a high degree of satisfaction with various life domains, including their mental health services and their general health status. (Abstract shortened by UMI.)
| Identifer | oai:union.ndltd.org:LACETR/oai:collectionscanada.gc.ca:QMM.79049 |
| Date | January 2003 |
| Creators | McGrath, Brent M. |
| Contributors | Tempier, Raymond (advisor) |
| Publisher | McGill University |
| Source Sets | Library and Archives Canada ETDs Repository / Centre d'archives des thèses électroniques de Bibliothèque et Archives Canada |
| Language | English |
| Detected Language | English |
| Type | Electronic Thesis or Dissertation |
| Format | application/pdf |
| Coverage | Master of Science (Department of Psychiatry.) |
| Rights | All items in eScholarship@McGill are protected by copyright with all rights reserved unless otherwise indicated. |
| Relation | alephsysno: 001975887, proquestno: AAIMQ88264, Theses scanned by UMI/ProQuest. |
Page generated in 0.0022 seconds